Background-Pathological stresses induce heart failure in animal models through activation of multiple cardiac transcription factors (TFs) working cooperatively. However, interactions among TFs in human heart failure are less understood. Here, we use genomic data to examine the evidence that 5 candidate TF families coregulate gene expression in human heart failure. Methods and Results-RNA isolates from failing (nϭ86) and nonfailing (nϭ16) human hearts were hybridized with Affymetrix HU133A arrays. For each gene on the array, we determined conserved MEF2, NFAT, NKX , GATA , and FOX binding motifs within the Ϫ1-kb promoter region using human-murine sequence alignments and the TRANSFAC database. Across 9076 genes expressed in the heart, TF-binding motifs tended to cluster together in nonrandom patterns within promoters of specific genes (P values ranging from 10 Ϫ2 to 10 Ϫ21 ), suggesting coregulation. We then modeled differential expression as a function of TF combinations present in promoter regions. Several combinations predicted increased odds of differential expression in the failing heart, with the highest odds ratios noted for genes containing both MEF2 and NFAT binding motifs together in the same promoter region (peak odds ratio, 3.47; Pϭ0.005).
B asic research has shown that pathological stresses promote heart failure via activation of cardiac transcription factors (TFs). 1, 2 These TFs integrate upstream stress signals and interact with each other and with coregulators to induce a fetal gene program that mediates cardiac myocyte hypertrophy and failure. However, the role of TFs in human heart failure has been difficult to study because transgenic techniques used to study animal models cannot be applied to human subjects.
Clinical Perspective on p 219
In a previous study, we used computational approaches that integrate human gene-expression data with genome sequence data to identify TFs associated with advanced human heart failure. 3 We found that many of the hypertrophic TFs identified in murine models were associated with human disease, and we identified a new association between fork-head (FOX) TFs and human heart failure. This initial study focused on identifying individual TFs associated with differentially expressed heart failure genes. However, there is substantial evidence from animal models that cardiac TFs function cooperatively with each other and with coactivators and repressors in their regulation of gene expression. 4 Here, we extend our previous findings by examining the evidence that combinations of specific cardiac TFs (MEF2, NFAT, NKX, GATA, and FOX) regulate gene expression in human heart failure.
Methods

Patients
Human myocardium was collected using a protocol approved by our institutional review board. Myocardium was obtained from patients undergoing heart transplantation for advanced systolic heart failure because of idiopathic dilated cardiomyopathy (nϭ86) and from nonfailing controls deemed unsuitable for transplantation (nϭ16) as described previously. 5 No subjects received mechanical support with left ventricular assist devices. All patients with heart failure had New York Heart Association class 3 to 4 symptoms and left ventricular systolic dysfunction, with meanϮSD ejection fraction of 11Ϯ5%. Nonfailing controls had normal left ventricular function with mean ejection fraction of 56Ϯ7% (Pϭ0.0001 versus failing by t test). Subjects with idiopathic dilated cardiomyopathy (50Ϯ12 years) were slightly younger than controls (57Ϯ12; Pϭ0.03 by t test). RNA isolation and microarray hybridization with Affymetrix HU133A arrays were performed as described previously. 5 These data represent a subset of those in our previous analysis, which focused on associations between individual TFs and gene expression in heart failure. 3 Expression data are available for download via NCBI gene expression omnibus (GSE472).
Study Design
Our study design is summarized in Figure 1 . For each gene on the Affymetrix HU133A array, the corresponding promoter region sequence was pulled from the University of California, Santa Cruz, genome database (www.genome.ucsc.edu) using the RefSeq gene ID, and the TRANSFAC database (www.transfac.de) was used to determine TF-binding motifs within portions of these promoters that showed evolutionary conservation. We restricted our focus to binding motifs for the 5 TF families of interest: MEF2, NFAT, NKX, GATA, and FOX. Our underlying assumption was that for a group of TFs to cooperatively regulate the expression of a given gene, their binding motifs must occur together within the promoter region of that gene. Hence, we first examined patterns of cooccurrence of TF-binding motifs in promoter regions across all genes expressed in the myocardium and examined the evidence that these patterns were nonrandom. We then modeled differential expression as a function of specific combinations of TF-binding motifs to identify groups of TFs that seem to regulate myocardial gene expression cooperatively. All analyses were carried out in R 2.6 (www.r-project.org; MASS and maanova libraries), Bioconductor tools (www.bioconductor.org; affy library), and permutation programs developed specifically for the project. 6
Integration of Datasets
Affymetrix gene-expression data were normalized and adjusted for background signal using robust multiarray analysis. 7 Probesets with expression values Ͻ91 U (log 2 ϭ6.5) in all patients were removed. Based on a previous work, this filtering removes genes that are near background levels of detection. 3, 8 These normalized, filtered datasets were then linked to promoter region binding motif data. For each unique gene represented on the HU133A array, we determined the Ϫ1-kb putative promoter sequences using the RefSeq gene annotation in the University of California, Santa Cruz, database. We then used the positional weight matrices (PWMs) in the TRANSFAC database of vertebrate TFs to determine TF-binding motifs within these promoters. Of note, in our previous study, we used a 5-kb promoter region. Here, we chose a 1-kb promoter region based on an analysis of the frequency of TF-binding motifs (see online-only Data Supplement). Our analysis used all PWMs in TRANSFAC that correspond to 1 of the 5 candidate TF families of interest. Assignment of PWMs to TF families was based on our previously reported clustering of all PWMs TRANFAC. 3 The presence/absence call for a PWM in a promoter region was made using our previously reported, phylogenetic footprinting approach, which combines significance of PWM match score with the human-mouse conservation. 3, 9 
Cooccurrence of TF-Binding Motifs in Promoters of Cardiac Genes
We first summarized the data according to the specific combinations of TFs that were identified in the promoters of cardiac genes. On the basis of the overall frequencies of each TF family across all genes, we computed the frequency of each TF combination expected under the assumption that the occurrences of each TF family were randomly, and independently, distributed across the genes. We then used an exact binomial test to test the null hypothesis that the observed frequency of genes for each specific TF combination was consistent with that expected under the random distribution model.
Assessment of Differential Gene Expression
To compare the expression in failing versus nonfailing hearts, we computed 2-sample T statistics for each probeset using a shrinkage estimate of the variance. 10 On the basis of the magnitude of the maximum observed T statistic (T max ) across probesets that mapped to each unique gene, we assigned each gene to 1 of 2 groups ("differentially expressed" or "unchanged"). In considering how TFs regulate gene expression in heart failure, we hypothesized that TFs regulate multiple genes simultaneously, with the involved genes demonstrating a wide range of levels of differential expression. Thus, rather than modeling a continuous measure of differential expression, we used 2 cut points as a threshold for differential expression, T max Ͼ2.00 or T max Ͼ3. 16 , to designate a gene as either differentially expressed or unchanged. Because our determination of differential expression is subject to error, we used 2 different thresholds to assess the sensitivity of our results to this determination. We repeated this procedure 5000 times after permuting the failing/ nonfailing status of the subjects using sampling without replacement. We used the resulting subject-level permutation-based T max values, an approach that accounts for dependencies among genes, to estimate the proportion of genes misclassified as differentially expressed (false-discovery rate), the proportion of genes misclassified as unchanged, and the overall misclassification rate at the 2 thresholds for differential expression. 11, 12 
Modeling Differential Expression as a Function of TF Combinations
The binary indicators described previously were used as the outcome in logistic regression models to indicate a gene that demonstrated differential expression in failing versus nonfailing hearts. Models were constructed to examine the association of different patterns of TF family occurrence and cooccurrence with the odds of differential expression. Associations were examined between the odds of differential expression and the presence of (1) at least 1 PWM associated with each specific TF family, (2) increasing numbers of TF families, and (3) specific combinations of TF families. The models were specified a priori, and no variable selection was carried out. For all models, the reference group was genes that lacked PWMs from all 5 TF families.
The assumption of independent outcomes needed for valid inference from a logistic regression model is violated by the correlations between genes. To address this, we used a modified logistic regression approach, similar to that of the "safe" procedure, based on permutations of subject status. 13 For models 2 and 3, global P values were determined by comparing the deviance change for the null and full models from the observed data to the distribution of the deviance 
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change for each of the 5000 subject-level permutations. If the global P value achieved significance, subject-level permutation P values for individual terms in each model were determined using Wald statistics.
We performed additional analyses to determine whether the 5 TF families chosen for this study revealed associations beyond randomly selected 5-family TF combinations. We grouped all 546 TFs in TRANFAC into 190 unique TF families based on the similarity of TF-binding motifs as described previously. 3 Using 25 000 replications, we first randomly sampled 5 TF families and determined the number of associated genes. For each replicate, we computed the odds of differential expression for genes with the 5 TF families relative to the odds of differential expression for genes with none of the 5 TF families.
Hypothesis Testing
Statistical significance was declared for PϽ0.05, and marginal significance was noted for P values between 0.05 and 0.10. Exact binomial tests were corrected for multiple hypothesis testing using a Bonferroni correction. For the logistic regression models, we addressed the issue of false-positives by carrying out a single global test of significance for each model. Only if that test was significant, test statistics for the individual terms in the model were considered. To retain statistical power, P values for these individual tests were not adjusted for multiple comparisons, but were instead used in combination with the odds ratio (OR) to determine combinations of TFs of particular interest.
Results
Cooccurrence of TF-Binding Motifs in Promoters of Cardiac Genes
After normalization, filtering, and mapping of microarray data to RefSeq, 9076 genes were detected in human myocardium at levels above background. Tables 1 and 2 describe the prevalence of TF families within the promoters of these genes and the PWMs that comprise these families. TF families are represented by different numbers of unique PWMs in TRANSFAC; FOX was most heavily represented with a total of 27 PWMs, whereas NFAT was represented by only 2 and NKX by only 8. A total of 87% of the 9076 cardiac genes were associated with at least one of the 5 TF families of interest. GATA (62%) and FOX (40%) were most common whereas NFAT (13%) and MEF2 (19%) occurred less frequently. For each TF family, the median number of matching PWMs within a particular promoter region was 1, except for the GATA family that had a median of 2 PWMs per promoter. Table 2 shows that most genes (64%) were associated with either 1 or 2 TF families, whereas Ͻ1% of genes were associated with all 5 TF families. Figure 2A indicates that the TF-binding motifs of interest were not distributed randomly across the genes, but tended to cluster together within a subset of cardiac genes. In particular, the number of genes with binding sites for 4 or 5 TF families within the same promoter was substantially higher than expected by chance (Ϸ2-to 3-fold increase). Figure 2B shows this finding in more detail by comparing the observed versus expected frequency of TF cooccurrence within the same promoter for all possible combinations of our candidate TFs. For most combinations with 4 or 5 TF families, the number of observed genes greatly exceeded that expected by chance, with Bonferroni-corrected P values ranging from 10 Ϫ3 to 10 Ϫ21 . By contrast, the observed versus expected values tended to be similar for combinations of 3 TFs, and for 2 or 1 TFs, we often found that the observed value was smaller than expected. Thus, binding sites for the 5 cardiac TF families investigated tend to cluster together within promoters of specific cardiac genes, with strong evidence for higher order clusters of 4 or 5 TFs. We repeated our analysis using combinations of 5 randomly selected TFs and found that clustering of 5 binding motifs within promoters is rare and unlikely to occur by chance (Data Supplement). These findings raise the possibility that MEF2, NFAT, NKX, GATA, and FOX cooperatively regulate gene expression in the human heart.
Differential Gene Expression
We next determined which among the 9076 cardiac genes studied showed evidence for differential expression in heart failure compared with controls, and which genes appeared unchanged. In practice, choosing a threshold for differential expression involves tradeoffs. Choosing a stringent threshold results in a differentially expressed group with little contamination by unchanged genes (ie, low false-discovery rate); however, a number of differentially expressed genes will be misclassified into the "unchanged" group. Conversely, choosing a less stringent threshold correctly assigns more of the differentially expressed genes to the correct group, but at the price of increased contamination of the differentially ex- pressed group by unchanged genes. Here, we chose 2 thresholds, T max Ͼ2.0 and T max Ͼ3.2, carrying out separate analyses with the rationale that important results with respect to TF coregulation should be consistent across both analyses.
Using a cutoff of T max Ͼ2.0 resulted in assignment of 3579 genes (39%) to the differentially expressed group compared with a substantially smaller number, 1772 genes (20%), for the more stringent cut point of T max Ͼ3.2 (Table 3 ). Based on subject-level permutations, the stringent cut point of T max Ͼ3.2 yielded a low false-discovery rate of 1% for the differentially expressed group, but a high misclassification rate of 34% for the unchanged group, indicating that about one third of the genes classified as unchanged are actually differentially expressed. By contrast, using a more liberal cut point of T max Ͼ2 yielded a false-discovery rate of 9% for the differentially expressed group and a more reasonable misclassification rate of 18% for the unchanged group. The overall misclassification rate was lower for the more liberal T max Ͼ2 cut point.
Association Between TF Combinations and Gene Expression
After classifying genes as differentially expressed or unchanged, we then used a series of logistic regression models to test the association between the presence of specific combinations of TF-binding motifs in the promoter region and odds of differential expression in heart failure across all 9076 cardiac genes. Table 4 summarizes the odds of differential expression associated with the presence of each individual TF family and with the total number of TF families present in the promoter. Results for the 2 T max cut points were similar, although the OR and the associated statistical significance were generally greater for the higher cut point. Compared with a reference set of genes that do not contain any binding sites for our TFs of interest, the presence of at least one PWM from any of the candidate TF families was associated with a small, but statistically significant or marginally significant odds of increased differential expression. Increasing numbers of TF families were associated with increasing odds of differential expression (global Pϭ0.035 for T max Ͼ2.0; global Pϭ0.0006 for T max Ͼ3.2). Genes that contained PWMs from all 5 TF families had a 2.1-(T max Ͼ2) to 3.2-fold (T max Ͼ3.2) increase in the odds of differential expression compared with a reference set with none of the TF families of interest. Because increasing numbers of TF families implies increasing numbers of PWMs (Table 2) , we added a term describing the number of PWMs to the model for TF family number. The addition of this term to this model did not substantively alter the findings in Table 4 (data not shown). These results suggest that the presence of multiple binding motifs together within the same promoter region substantially increases the likelihood of differential expression in the failing human heart. Table 5 shows the association between specific TF family combinations and odds of differential expression. Here, each gene was assigned to either the baseline reference group or to 1 of 32 categories shown in Table 5 . We then used 2 multivariable logistic regression models (1 for each T max threshold) to determine associations between these TF categories and odds of differential expression. Global P values for each of the 2 models indicated evidence of significant associations for both thresholds (Pϭ0.028 for T max Ͼ2.0; Pϭ0.001 for T max Ͼ3.2). As with the earlier models (Table  4) , the association with a specific TF combination was typically more pronounced for the higher T max threshold. Five combinations showed statistically significant associations (PϽ0.05) at both thresholds and are indicated in boldface in the table. Of these, the largest ORs were for the 2-family combination of MEF2 with NFAT (OR, 3.47/3.03 for T max Ͼ 2.0/T max Ͼ3.2) and for all 5 TF families (OR, 2.1/3.2). For comparison, we randomly generated sets of 5 TFs using data from TRANSFAC and repeated our analysis (Data Supplement). Among random TF combinations with at least 50 associated genes, the median OR for association with differential expression was only 0.9, and the upper 95th percentile was 1.4. This finding further supports the hypothesis that our combination of 5 cardiac TF families is associated with an unusually high odds of differential gene expression.
Further examination of all the results in Table 5 suggested that any TF combination containing both MEF2 and NFAT tended to fall among the higher ORs. For example, 4 of 5 of the highest ORs for either T max cut point contained both MEF2 and NFAT. Figure 3 explores this finding further by plotting the ORs from both models and highlighting all TF combinations that contain both MEF2 and NFAT. As shown, any TF combination containing both MEF2 and NFAT tended to consistently rank among the highest ORs in our study. We note that the findings in Table 5 and Figure 3 were very similar when we included a term in the model that adjusted for the total number of PWMS associated with each gene (results not shown). Thus, among the candidate TF combinations investigated, our analysis suggests that genes jointly targeted by MEF2 and NFAT show the strongest evidence for differential expression in the failing human heart.
In the Data Supplement, we provide a browseable database of the human cardiac MEF2/NFAT target genes and promoters identified by our analysis. We also provide a heatmap that summarizes changes in expression of these genes across samples and an ontology analysis of biological processes to which they contribute.
Discussion
In this study, we integrated cardiac gene-expression data, promoter sequence data, and TF-binding motif data to ask whether candidate hypertrophic TFs (MEF2, NFAT, NKX, GATA, and FOX) coregulate gene expression in the failing human heart. We found that (1) binding motifs for these TFs tend to cluster in a subset of cardiac promoters, with strong evidence of higher-order clusters; (2) the greater the number of binding motifs, the greater the odds of differential expression in heart failure; and (3) genes containing binding motifs for both MEF2 and NFAT show the strongest likelihood of differential expression among the combinations studied. Taken together, these findings suggest that regulation of myocardial gene expression by combinatorial action of MEF2 and NFAT may play an important role in human heart failure.
Numerous animal studies suggest that cardiac hypertrophy and heart failure are mediated to a large extent by cardiac TFs integrating upstream stress signals and acting in a combinatorial fashion to regulate the expression of "fetal" genes in cardiac myocytes. 14 -16 This paradigm has developed largely based on evidence from murine models and cell culture through the use of transgenic techniques that explore the function of specific TFs. However, these techniques cannot be applied to human subjects and, as such, it has been difficult to investigate the overall paradigm, and the specific TFs identified, in human disease.
Our study provides the first evidence supporting combinatorial regulation of myocardial gene expression in the human heart. More broadly, we show that integrating diverse sources of whole genome data can provide insight into the pathogenesis of human cardiovascular disorders.
Our finding regarding MEF2 and NFAT is of particular interest because these factors play a critical role in the pathogenesis of heart failure in murine models. MEF2 (myo- 20 and in vivo reportergene studies demonstrate endogenous MEF2 activation in response to hypertrophic stimuli. 21 These and other studies have established MEF2 TFs as critical mediators of hypertrophy and heart failure in mice. Likewise, NFAT TFs are critical for cardiac development and are well-established mediators of stress-induced hypertrophy and failure. The 4 NFAT TFs (NFATc1-4) are expressed in the myocardium and localized to the cytoplasm. In response to increases in intracellular calcium, the phosphatase calcineurin dephosphorylates NFAT TFs, which are then translocated to the nucleus where they alter gene expression and induce hypertrophy and failure in animals. 14 Interestingly, previous in vitro studies also found that MEF2 and NFAT can cooperatively regulate gene expression. In T cells, stimulation of the T-cell antigen receptor induces expression of Nu77 via MEF2/NFAT interactions that are mediated by physical association between MEF2, NFAT, and p300, a histone acetyl transferase that enhances transcription via chromatin unfolding. 22 NFAT-MEF2 interactions have also been identified in the development of slow-twitch skeletal muscle fibers and expression of myoglobin. 23, 24 Thus, our findings in human heart failure are consistent with experimental data from a variety of different model systems and extend the paradigm of coregulation by MEF2/NFAT to the failing human heart.
Although the principal aim of this study was to explore evidence for coregulation by cardiac TFs, we have also identified a number of specific target genes that show altered expression in the failing heart and contain binding sites for cardiac TFs in their 1-kb promoter region (see Data Supplement for a browseable database of target genes). These genes may be novel contributors to the pathophysiology of heart failure and warrant focused study. An analysis of ontological terms associated with these genes showed enrichment of terms related to muscle and vascular tissue as well as organ development and morphogenesis (Data Supplement). This is consistent with the concept that cardiac remodeling in humans represents, in part, a reactivation of fetal/developmental pathways. Many of these specific target genes encode components of the sarcomere (eg, MYOT, NEBL, and ITGB1BP2), the cytoskeleton (eg, ADD3, PALLD, and SORBS2), and the interstitial matrix (eg, LUM, COL3A1, TNXB, OGN, and COL16A1). However, a number of TFs and coregulators were also identified as MEF2/NFAT targets (eg, HMGN3, E2F, MAX, SNW1, TCF12, SMAD7, GTF2E1, KLF6, and ATF6). Of note, MEF2C and NFATC1 were, themselves, identified as target genes that contain upstream NFAT and MEF2 binding sites and that were induced in the failing heart. These findings are consistent with a model in which hypertrophic TFs induce the expression of a network of secondary TFs to mediate their effects, and offer the intriguing possibility that feedback loops may exist between MEF2/NFAT activity and transcription of the MEF2C and NFATC1 genes.
Although this is a human study performed with rigorous approaches, several limitations warrant discussion. First, this is an observational study that associates groups of TFs with heart failure, but cannot prove a causal relationship. Such proof requires experimental manipulation of myocardial TF activity in the human heart, which is currently not feasible. Second, although the total sample size is large for a gene expression study, our control group is relatively small owing to the difficulty in acquiring nonfailing human cardiac tissue. In addition, the study population had advanced stage heart failure, and findings might differ in earlier stages of disease. Third, to build on results from animal studies, we selected 5 candidate TF families based on the current state of knowledge and on previous analyses. 3 We may have ignored the potential contributions of other TFs, and ongoing work using an inclusive exploratory approach across the entire TRANSFAC database should help resolve this question.
Methodological challenges arose during the course of our analysis. As discussed in our previous work, 3 studying TF-binding motifs prevents us from distinguishing the effects of individual members of a TF family, because all members recognize highly similar binding motifs. This could bias our analysis toward finding no associations, because we group TFs that may not contribute to heart failure (eg, GATA1) along with those that probably do (eg, GATA4). Thus, our results may underestimate the extent of coregulation by cardiac TFs. Although we used logistic regression to model differential expression as a binary outcome, a proportion of the genes in our study was undoubtedly misclassified (Table  3 ). Our previous study used a different method to assess differential expression and a more stringent threshold that yielded a smaller group of differentially expressed genes. 3 Despite these differences, the results of the current and original studies were consistent in identifying significant associations between the 5 individual TFs and differential gene expression, and the current study extends these findings by identifying groups of TFs that seem to coregulate gene expression. Another challenge was the natural variation in the frequency of the individual and combinations of TFs and the implications for statistical power. Thus if 2 TF combinations both have the same association with differential expression, but 1 combination occurs more frequently, the more frequent combination will tend to yield the lower P value in a hypothesis test. This emphasizes the need to focus on both the effect size (OR) and the level of statistical significance (P value) in the interpretation of our results. In the case of combinations containing MEF2 and NFAT, both the odd ratios ( Figure 3) and P values ( Table 5 ) indicated strong associations.
In conclusion, we provide genomic evidence for coregulation of myocardial gene expression by MEF2 and NFAT in advanced human heart failure. In doing so, this work extends the paradigm of combinatorial regulation of gene expression to the human heart and has identified target genes of biological interest. Future work will focus on testing the mechanistic role of these target genes using experimental models, and on using unbiased approaches to broadly screen combinations of all known TFs for association with human heart failure.
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